Track market-moving stories before they get noisy

Apella Capital LLC grew its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 16.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 43,902 shares of the company’s stock after acquiring an additional 6,239 shares during the period. Apella Capital LLC’s holdings in Merck & Co., Inc. were worth $6,269,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. BlackRock Inc. lifted its holdings in Merck & Co., Inc. by 0.5% in the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock worth $29,169,479,000 after buying an additional 1,073,507 shares during the period. State Street Corp increased its stake in shares of Merck & Co., Inc. by 0.9% during the second quarter. State Street Corp now owns 120,413,256 shares of the company’s stock valued at $15,573,754,000 after buying an additional 1,087,583 shares during the period. Wellington Management Group LLP increased its stake in shares of Merck & Co., Inc. by 2.3% during the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after buying an additional 1,934,312 shares during the period. Bank of America Corp DE raised its holdings in shares of Merck & Co., Inc. by 10.5% during the first quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock valued at $3,701,831,000 after acquiring an additional 2,919,780 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in shares of Merck & Co., Inc. by 3.5% during the fourth quarter. Invesco Ltd. now owns 20,546,185 shares of the company’s stock valued at $2,162,691,000 after acquiring an additional 701,249 shares in the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets Several research firms recently weighed in on MRK. Argus lifted their price target on shares of Merck & Co., Inc. from $145.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, August 25th. Barclays upped their price objective on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Cantor Fitzgerald lifted their target price on shares of Merck & Co., Inc. from $120.00 to $145.00 and gave the company a “neutral” rating in a research note on Thursday. Wolfe Research boosted their price target on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a research report on Tuesday, August 25th. Finally, Wall Street Zen downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Seventeen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and an average target price of $151.32.

View Our Latest Stock Analysis on Merck & Co., Inc. Merck & Co., Inc. Trading Down 0.2% Merck & Co., Inc. stock opened at $142.45 on Friday. Merck & Co., Inc. has a 12 month low of $82.01 and a 12 month high of $156.92. The company has a market capitalization of $351.45 billion, a price-to-earnings ratio of 113.96, a price-to-earnings-growth ratio of 6.42 and a beta of 0.21. The business’s fifty day simple moving average is $143.59 and its two-hundred day simple moving average is $128.16. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.Merck & Co., Inc.’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts predict that Merck & Co., Inc. will post 2.67 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement The firm also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were given a $0.85 dividend. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.4%. Merck & Co., Inc.’s payout ratio is 272.00%.

Key Merck & Co., Inc. News Here are the key news stories impacting Merck & Co., Inc. this week:

Positive Sentiment: The FDA approved WELIREG plus LENVIMA for adults with advanced renal cell carcinoma previously treated with a PD-1/PD-L1 inhibitor. The decision expands Merck’s oncology portfolio and could create another commercial opportunity beyond Keytruda. Merck also started a first-in-human trial using Cyprumed’s oral peptide-delivery platform, although that program remains at a very early stage. Merck Wins FDA Approval for WELIREG Plus LENVIMA in Kidney Cancer Positive Sentiment: Morgan Stanley maintained an “overweight” rating while trimming its price target modestly to $177, implying substantial upside based on the referenced price. The call indicates continued confidence in Merck’s long-term earnings and pipeline prospects. Morgan Stanley Raises Merck Analyst View Positive Sentiment: Merck’s shareholder dividend was highlighted as part of its income appeal, which may support investor interest while the company navigates product-cycle and patent risks. Merck Dividend Payment Neutral Sentiment: Cantor Fitzgerald raised its price target to $145 but retained a “neutral” rating, suggesting limited near-term upside and a cautious view of Merck’s growth outlook. Cantor Fitzgerald Merck Price Target Neutral Sentiment: Articles comparing Innoviva and Merck frame MRK as a large-cap pharmaceutical value candidate, but provide no new company-specific catalyst likely to materially change the stock’s valuation today. INVA vs. MRK: Which Stock Is the Better Value Option? Negative Sentiment: A Dutch court granted Halozyme an injunction blocking Merck’s subcutaneous Keytruda in eight European markets. The ruling could delay or restrict commercialization of a potentially more convenient Keytruda formulation and heightens litigation risk. Halozyme Wins Court Order Blocking Merck’s Keytruda SC in Europe Negative Sentiment: Industry analysis identifies Merck as particularly exposed to near-term generic competition as major products approach patent losses. That raises concerns about revenue durability and increases the importance of successful launches such as WELIREG. Pharma’s $500 Billion Patent Problem Insider Activity In other news, EVP David R. Maraldo sold 18,706 shares of the stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the transaction, the executive vice president directly owned 18,212 shares of the company’s stock, valued at $2,344,248.64. This represents a 50.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP David Williams sold 52,847 shares of the firm’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the transaction, the executive vice president owned 31,716 shares in the company, valued at approximately $4,084,069.32. This trade represents a 62.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is owned by corporate insiders.

Merck & Co., Inc. Profile (Free Report)

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.

Recommended Stories Five stocks we like better than Merck & Co., Inc. Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Toth Financial Advisory Corp purchased a new stake in Snowflake Inc. (NYSE:SNOW – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 2,200 shares of the company’s stock, valued at approximately $747,000.

Several other hedge funds have also recently bought and sold shares of SNOW. Congress Asset Management Co. boosted its stake in shares of Snowflake by 13.4% in the 3rd quarter. Congress Asset Management Co. now owns 35,643 shares of the company’s stock valued at $12,103,000 after purchasing an additional 4,223 shares in the last quarter. Polaris Financial Partners bought a new position in Snowflake during the 3rd quarter valued at about $51,000. Versant Capital Management Inc lifted its holdings in Snowflake by 104.4% during the 3rd quarter. Versant Capital Management Inc now owns 511 shares of the company’s stock valued at $174,000 after purchasing an additional 261 shares during the last quarter. Burkett Financial Services LLC acquired a new position in Snowflake in the third quarter valued at about $82,000. Finally, QRG Capital Management Inc. grew its stake in Snowflake by 67.9% during the second quarter. QRG Capital Management Inc. now owns 82,137 shares of the company’s stock worth $20,904,000 after buying an additional 33,218 shares during the last quarter. 65.10% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Snowflake In related news, Director Michael Speiser sold 50,338 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $324.06, for a total value of $16,312,532.28. Following the transaction, the director owned 26,036 shares in the company, valued at $8,437,226.16. This trade represents a 65.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Frank Slootman sold 289,685 shares of Snowflake stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $274.39, for a total value of $79,486,667.15. Following the completion of the sale, the director owned 28,535 shares of the company’s stock, valued at approximately $7,829,718.65. The trade was a 91.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 1,246,429 shares of company stock worth $396,227,952. 4.80% of the stock is owned by insiders.

Snowflake Stock Up 3.3% NYSE:SNOW opened at $343.90 on Friday. The stock’s fifty day moving average price is $329.72 and its two-hundred day moving average price is $247.89. Snowflake Inc. has a 52-week low of $118.30 and a 52-week high of $384.56. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.94 and a current ratio of 0.94. The company has a market cap of $121.33 billion, a price-to-earnings ratio of -108.14 and a beta of 1.35. Snowflake (NYSE:SNOW – Get Free Report) last announced its quarterly earnings data on Wednesday, September 2nd. The company reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.17. The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.48 billion. Snowflake had a negative return on equity of 46.32% and a negative net margin of 20.07%.The business’s quarterly revenue was up 35.1% compared to the same quarter last year. During the same period last year, the company earned $0.35 EPS. On average, analysts anticipate that Snowflake Inc. will post -1.46 EPS for the current year.

Wall Street Analysts Forecast Growth A number of research firms recently commented on SNOW. Canaccord Genuity Group increased their price target on Snowflake from $325.00 to $450.00 and gave the stock a “buy” rating in a research report on Thursday, September 3rd. Citizens Jmp lifted their price objective on Snowflake from $408.00 to $488.00 and gave the company a “market outperform” rating in a research report on Thursday, September 3rd. Wells Fargo & Company boosted their price objective on Snowflake from $500.00 to $525.00 and gave the stock an “overweight” rating in a research note on Thursday, September 3rd. Bank of America lifted their price target on Snowflake from $330.00 to $395.00 and gave the company a “buy” rating in a report on Wednesday, August 19th. Finally, Citigroup upped their price target on shares of Snowflake from $395.00 to $490.00 and gave the stock a “buy” rating in a research report on Thursday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, thirty-four have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $414.24.

Get Our Latest Analysis on Snowflake

Snowflake Profile (Free Report)

Snowflake Inc (NYSE: SNOW) provides a cloud-based data platform that enables organizations to store, process, analyze and share data. Its platform is designed to support data warehousing, data lakes, data engineering, data science, application development and artificial intelligence workloads in a single environment.

Snowflake’s services include cloud data storage and computing, data sharing and collaboration tools, governance and security capabilities, and access to third-party data through the Snowflake Marketplace.

Featured Stories Five stocks we like better than Snowflake Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push Want to see what other hedge funds are holding SNOW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Snowflake Inc. (NYSE:SNOW – Free Report).

Receive News & Ratings for Snowflake Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Snowflake and related companies with MarketBeat.com's FREE daily email newsletter.

GAMMA Investing LLC grew its position in CF Industries Holdings, Inc. (NYSE:CF – Free Report) by 616.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 54,379 shares of the basic materials company’s stock after buying an additional 46,790 shares during the quarter. GAMMA Investing LLC’s holdings in CF Industries were worth $6,797,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Farther Finance Advisors LLC increased its holdings in CF Industries by 2,298.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 97,462 shares of the basic materials company’s stock valued at $12,297,000 after acquiring an additional 93,399 shares in the last quarter. Sapient Capital LLC lifted its holdings in shares of CF Industries by 176.8% in the third quarter. Sapient Capital LLC now owns 13,939 shares of the basic materials company’s stock valued at $1,708,000 after purchasing an additional 8,904 shares in the last quarter. CoreCap Advisors LLC grew its position in shares of CF Industries by 340.6% in the third quarter. CoreCap Advisors LLC now owns 3,736 shares of the basic materials company’s stock valued at $467,000 after purchasing an additional 2,888 shares during the last quarter. Everhart Financial Group Inc. grew its position in shares of CF Industries by 306.5% in the third quarter. Everhart Financial Group Inc. now owns 13,753 shares of the basic materials company’s stock valued at $1,704,000 after purchasing an additional 10,370 shares during the last quarter. Finally, Vann Equity Management LLC increased its stake in shares of CF Industries by 127.3% during the 3rd quarter. Vann Equity Management LLC now owns 8,797 shares of the basic materials company’s stock worth $1,071,000 after purchasing an additional 4,926 shares in the last quarter. 93.06% of the stock is currently owned by hedge funds and other institutional investors.

More CF Industries News Here are the key news stories impacting CF Industries this week:

Positive Sentiment: Quarterly dividend maintained: CF Industries declared a quarterly dividend of $0.60 per share, equivalent to $2.40 annually and an indicated 2.1% yield. The dividend is payable November 30 to shareholders of record November 16. The continued payout may appeal to income-focused investors. CF Industries Declares Quarterly Dividend Positive Sentiment: Strong cash flow supports capital allocation: Recent analysis highlights CF Industries’ ability to use cash flow for strategic investments, debt reduction and shareholder returns. Continued cash generation could support growth and improve balance-sheet strength. CF Industries Strong Cash Flow Analysis Neutral Sentiment: Next earnings catalyst scheduled: CF Industries will report third-quarter and nine-month 2026 results after the market closes on November 4, followed by a conference call. Investors will be looking for evidence that operating performance and fertilizer-market conditions are improving. CF Industries Dividend and Earnings Schedule Neutral Sentiment: Analyst stance remains cautious: RBC Capital kept a Hold rating, while another recent report placed a $115 price target, suggesting limited near-term upside from current levels. RBC Capital Maintains Hold Rating Negative Sentiment: Prior earnings miss remains an overhang: CF Industries previously reported earnings and revenue below analyst expectations, despite year-over-year revenue growth. That performance may be contributing to investor caution until the November results provide updated guidance. CF Industries Trading Down 0.8% Shares of CF opened at $113.47 on Friday. CF Industries Holdings, Inc. has a fifty-two week low of $75.42 and a fifty-two week high of $141.96. The company has a market capitalization of $17.17 billion, a PE ratio of 8.41, a price-to-earnings-growth ratio of 0.22 and a beta of 0.53. The stock has a fifty day moving average of $123.88 and a two-hundred day moving average of $120.74. The company has a debt-to-equity ratio of 0.36, a quick ratio of 4.32 and a current ratio of 4.86. CF Industries (NYSE:CF – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The basic materials company reported $4.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.63 by ($0.90). The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.45 billion. CF Industries had a return on equity of 24.41% and a net margin of 27.12%.CF Industries’s revenue for the quarter was up 17.6% compared to the same quarter last year. During the same quarter last year, the business earned $2.37 EPS. As a group, analysts forecast that CF Industries Holdings, Inc. will post 13.9 EPS for the current year.

CF Industries Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Monday, November 30th. Shareholders of record on Monday, November 16th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend is Monday, November 16th. CF Industries’s dividend payout ratio (DPR) is presently 17.79%.

Wall Street Analysts Forecast Growth CF has been the topic of a number of recent research reports. Scotiabank upped their target price on CF Industries from $125.00 to $130.00 and gave the company an “outperform” rating in a research note on Monday, August 10th. BNP Paribas Exane dropped their price target on CF Industries from $140.00 to $120.00 and set a “neutral” rating for the company in a research report on Monday, June 15th. The Goldman Sachs Group cut their price target on CF Industries from $133.00 to $115.00 and set a “neutral” rating for the company in a report on Tuesday, June 23rd. Weiss Ratings upgraded CF Industries from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, September 16th. Finally, UBS Group increased their price objective on CF Industries from $115.00 to $123.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $121.11.

Get Our Latest Stock Report on CF Industries

CF Industries Company Profile (Free Report)

CF Industries Holdings, Inc (NYSE: CF) is a major global producer of nitrogen fertilizer and other nitrogen-based products. The company manufactures ammonia, granular urea, urea ammonium nitrate (UAN), ammonium nitrate and specialty nitrogen products used in agriculture, industrial applications and emissions-control systems.

CF Industries operates a network of production facilities in the United States, Canada and the United Kingdom, serving agricultural and industrial customers in North America and international markets.

Featured Articles Five stocks we like better than CF Industries Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push Want to see what other hedge funds are holding CF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CF Industries Holdings, Inc. (NYSE:CF – Free Report).

Receive News & Ratings for CF Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CF Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Bell Asset Management Ltd cut its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 48.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,833 shares of the company’s stock after selling 10,062 shares during the quarter. AbbVie makes up approximately 1.0% of Bell Asset Management Ltd’s portfolio, making the stock its 23rd largest holding. Bell Asset Management Ltd’s holdings in AbbVie were worth $2,834,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ABBV. Burk Holdings LLC bought a new position in AbbVie in the 2nd quarter worth approximately $30,000. Abound Financial LLC purchased a new stake in shares of AbbVie during the fourth quarter worth $32,000. Merkkuri Wealth Advisors LLC bought a new position in shares of AbbVie in the first quarter worth $34,000. Marquette Asset Management LLC grew its position in shares of AbbVie by 52.2% in the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after purchasing an additional 48 shares in the last quarter. Finally, Phillip James Consulting Co. bought a new stake in shares of AbbVie during the 4th quarter valued at $36,000. Institutional investors own 70.23% of the company’s stock.

Insider Activity at AbbVie In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes ABBV has been the subject of a number of recent analyst reports. Rothschild & Co Redburn lifted their target price on AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. HSBC upped their target price on shares of AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings upgraded AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, August 4th. Finally, Morgan Stanley lifted their price target on AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $276.64. Read Our Latest Stock Analysis on AbbVie

AbbVie News Summary Here are the key news stories impacting AbbVie this week:

Positive Sentiment: FDA breakthrough designations for Temab-A: The FDA granted two Breakthrough Therapy Designations to investigational telisotuzumab adizutecan (Temab-A/ABBV-400) for colorectal cancer and non-small cell lung cancer. The designations can accelerate development and regulatory review, while highlighting the potential of AbbVie’s antibody-drug conjugate portfolio. They do not, however, represent an approval or guarantee of commercial success. AbbVie Temab-A FDA Breakthrough Therapy Designations Positive Sentiment: Strong Phase 3 lymphoma data: AbbVie and Genmab reported that epcoritamab plus R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The result supports the potential for broader use of Epkinly/Epkinly and adds another meaningful pipeline catalyst. AbbVie and Genmab Epcoritamab Phase 3 Results Positive Sentiment: Higher analyst price targets: JPMorgan raised its AbbVie target to $300 from $285 and maintained an Overweight rating. Cantor Fitzgerald also raised its target, to $290 from $285, and reiterated Overweight. The revisions indicate analysts see additional upside based on AbbVie’s pipeline and growth outlook. Negative Sentiment: Dividend sustainability concerns: A report highlighted AbbVie’s roughly 190% payout ratio, meaning reported earnings are below the dividend distributed. While noncash charges and other accounting factors can distort this measure, the elevated ratio raises questions about long-term dividend coverage and could weigh on income-focused investors. AbbVie Dividend Payout Concerns AbbVie Price Performance NYSE:ABBV opened at $272.20 on Friday. The company has a market capitalization of $480.92 billion, a price-to-earnings ratio of 76.89, a PEG ratio of 1.23 and a beta of 0.24. The business has a 50 day moving average of $258.56 and a 200 day moving average of $236.35. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $274.94.

AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts anticipate that AbbVie Inc. will post 14.01 EPS for the current year.

AbbVie Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio is currently 195.48%.

AbbVie Company Profile (Free Report)

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

See Also Five stocks we like better than AbbVie Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

Artemis Investment Management LLP reduced its holdings in shares of Micron Technology, Inc. (NASDAQ:MU – Free Report) by 93.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,634 shares of the semiconductor manufacturer’s stock after selling 61,439 shares during the quarter. Artemis Investment Management LLP’s holdings in Micron Technology were worth $4,936,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in MU. Andar Capital Management HK Ltd boosted its stake in Micron Technology by 856,960.3% during the 2nd quarter. Andar Capital Management HK Ltd now owns 34,282,413 shares of the semiconductor manufacturer’s stock valued at $39,571,847,000 after acquiring an additional 34,278,413 shares during the last quarter. Primecap Management Co. CA bought a new stake in shares of Micron Technology in the 2nd quarter worth about $22,182,263,000. Legal & General Group Plc bought a new stake in shares of Micron Technology in the 2nd quarter worth about $8,402,393,000. Situational Awareness LP raised its stake in shares of Micron Technology by 1,149.0% in the 2nd quarter. Situational Awareness LP now owns 4,828,786 shares of the semiconductor manufacturer’s stock valued at $5,573,819,000 after purchasing an additional 5,289,124 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Micron Technology in the 2nd quarter valued at about $3,761,237,000. Institutional investors and hedge funds own 80.84% of the company’s stock.

Insider Activity In other news, EVP Sumit Sadana sold 15,000 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $934.29, for a total value of $14,014,350.00. Following the transaction, the executive vice president directly owned 191,021 shares of the company’s stock, valued at approximately $178,469,010.09. This represents a 7.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Sanjay Mehrotra sold 40,000 shares of the stock in a transaction on Friday, August 21st. The stock was sold at an average price of $968.90, for a total value of $38,756,000.00. Following the sale, the chief executive officer owned 264,503 shares of the company’s stock, valued at approximately $256,276,956.70. This represents a 13.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 95,879 shares of company stock worth $90,939,466 in the last 90 days. Company insiders own 0.24% of the company’s stock.

Micron Technology News Summary Here are the key news stories impacting Micron Technology this week: Positive Sentiment: Strong earnings and forward guidance support the growth outlook. Micron reported fiscal fourth-quarter revenue of $54.23 billion and adjusted earnings of $33.42 per share, both ahead of expectations. Management also projected fiscal first-quarter 2027 adjusted EPS of $37.15-$39.15, implying another sequential increase. Micron’s Latest Earnings Reveal Why the AI Memory Supercycle Could Run for Years Positive Sentiment: AI-related demand remains a major catalyst. More than 75% of Micron’s fiscal 2027 output is reportedly committed, while customers are already discussing 2028 allocations. Record DRAM revenue and surging enterprise SSD demand suggest data-center customers are securing memory supply well in advance. Micron: This Memory Cycle Could End Differently Positive Sentiment: Analyst support remains strong. Zacks upgraded Micron to “Strong Buy,” while D.A. Davidson raised its price target to $3,000 and maintained a Buy rating, citing a potential multiyear shortage driven by AI infrastructure spending. Micron & 2 Profitable Stocks to Buy in October for Big Upside Neutral Sentiment: Valuation and cyclicality remain debated. Bullish analysts view Micron’s roughly six-to-seven-times forward earnings valuation as inexpensive, but skeptics warn that margins may be near a peak and that memory prices could eventually normalize. A $600 million settlement with Netlist also removes a legal overhang but adds a material cost. Micron Technology, Netlist Settle Patent Dispute for $600 Million Negative Sentiment: Investors reacted negatively to weaker-than-expected AI revenue concerns. A report that OpenAI’s annualized revenue was below expectations triggered a broader selloff in AI and semiconductor stocks. Analysts said the figure may reflect reporting differences rather than a deterioration in AI demand, but the news heightened concern about crowded AI valuations. Micron, Nvidia and AI chip stocks fall as report on OpenAI’s revenue causes undue concern Negative Sentiment: A Taiwan labor dispute adds operational risk. Workers at Micron’s major Taiwan manufacturing sites authorized a strike over bonus changes. No walkout has been announced, but a disruption could threaten production and increase costs. Micron’s Taoyuan union in Taiwan secures authorisation to strike Negative Sentiment: Samsung’s record profit did not reassure memory investors. Although Samsung reported sharply higher operating profit, the slower pace of growth and concerns that the memory cycle is nearing a peak reinforced fears that Micron’s exceptional earnings growth may decelerate. The Memory Trade Cools After Samsung’s Preliminary Results Disappoint Micron Technology Stock Performance NASDAQ:MU opened at $1,035.84 on Friday. The firm has a market cap of $1.17 trillion, a price-to-earnings ratio of 13.96, a price-to-earnings-growth ratio of 0.19 and a beta of 2.22. Micron Technology, Inc. has a twelve month low of $179.61 and a twelve month high of $1,255.00. The company has a 50-day moving average of $975.93 and a 200-day moving average of $840.54. The company has a current ratio of 3.31, a quick ratio of 2.94 and a debt-to-equity ratio of 0.03.

Micron Technology (NASDAQ:MU – Get Free Report) last announced its quarterly earnings data on Wednesday, September 30th. The semiconductor manufacturer reported $33.42 EPS for the quarter, beating analysts’ consensus estimates of $31.77 by $1.65. Micron Technology had a return on equity of 92.62% and a net margin of 63.80%.The company had revenue of $54.23 billion during the quarter, compared to the consensus estimate of $51.33 billion. During the same quarter in the prior year, the firm earned $3.03 EPS. The company’s quarterly revenue was up 379.1% compared to the same quarter last year. Micron Technology has set its Q1 2027 guidance at 37.150-39.150 EPS. Analysts forecast that Micron Technology, Inc. will post 175.82 earnings per share for the current fiscal year.

Micron Technology Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 29th. Investors of record on Wednesday, October 14th will be given a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 0.1%. The ex-dividend date of this dividend is Wednesday, October 14th. Micron Technology’s payout ratio is presently 0.81%.

Analyst Ratings Changes MU has been the subject of a number of research reports. CLSA reiterated an “outperform” rating and issued a $1,700.00 price target on shares of Micron Technology in a research note on Friday, October 2nd. JPMorgan Chase & Co. increased their target price on Micron Technology from $550.00 to $1,540.00 and gave the stock an “overweight” rating in a report on Thursday, June 25th. Seaport Research Partners reiterated a “buy” rating on shares of Micron Technology in a research report on Friday, August 14th. Needham & Company LLC reiterated a “buy” rating and issued a $1,650.00 price target on shares of Micron Technology in a report on Thursday, October 1st. Finally, Daiwa Securities Group raised their price objective on Micron Technology from $1,600.00 to $1,700.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, forty-one have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $1,407.88.

Check Out Our Latest Analysis on MU

Micron Technology Company Profile (Free Report)

Micron Technology, Inc is a semiconductor company that develops and manufactures memory and storage solutions. Its product portfolio includes dynamic random-access memory (DRAM), NAND flash memory, three-dimensional XPoint-related technologies, solid-state drives, and high-bandwidth memory products designed for demanding computing applications.

The company serves customers across the data center, artificial intelligence, networking, automotive, industrial, mobile, consumer electronics, and embedded markets.

Featured Articles Five stocks we like better than Micron Technology Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push

Receive News & Ratings for Micron Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Micron Technology and related companies with MarketBeat.com's FREE daily email newsletter.

Exploratory data presented at Fall Clinical 2026 showed broader biomarker changes with Taltz and Zepbound vs. Taltz alone as early as Week 12 in first-of-its-kind TOGETHER-PsO study

, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new exploratory data from the TOGETHER-PsO Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared with Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight with at least one additional weight-related comorbid condition. The prespecified analysis, presented at the 2026 Fall Clinical Dermatology Conference in Las Vegas, provides new insights suggesting an immunometabolic relationship between psoriasis and obesity. These data showed that when Taltz and Zepbound were used together, changes were observed in more psoriasis disease-associated and metabolic biomarkers compared to Taltz monotherapy. In the U.S., approximately 61% of people with psoriasis also have obesity or overweight with at least one weight-related comorbidity.1 

"People living with psoriasis and obesity carry a compounded burden that extends beyond what is visible, yet these conditions are too often viewed through separate treatment lenses," said Mark Genovese, M.D., senior vice president of Lilly Immunology development. "The broader biomarker changes observed with Taltz and Zepbound, including those associated with skin clearance, may point to a meaningful relationship between immune and metabolic biology. Along with previously reported clinical outcomes, these findings support a more comprehensive approach to psoriasis care that also addresses obesity for people managing both conditions."

This analysis examined circulating proteins and gene expression in the blood to better understand the biological change observed when patients were treated concomitantly with Taltz and Zepbound vs. Taltz alone. At Week 36, observed changes in psoriasis-specific, immune and metabolic biomarkers in both the Taltz and Zepbound and Taltz monotherapy treatment arms were consistent with the known biological effects of each medicine when used for their approved indications. Notably, Taltz and Zepbound used together were associated with broader biomarker responses compared to Taltz alone as early as Week 12. This included changes in more proteins (482 vs. 140 differentially expressed proteins) and genes (467 vs. 16 differentially expressed genes) by Week 36.

Further, the analysis showed greater reductions in inflammatory immune activity with Taltz and Zepbound compared with Taltz alone, including changes related to neutrophils, a type of immune cell involved in inflammation. Changes in a subset of neutrophil-associated markers mediated a portion of the additional Psoriasis Area and Severity Index (PASI) response seen with Taltz and Zepbound vs. Taltz alone.

"This analysis provides new insights into the potential connected immune and metabolic biology in people with psoriasis and obesity," said James G. Krueger, M.D., Ph.D., Professor and Laboratory Head, The Rockefeller University. "What is most compelling is these findings identified differences in inflammatory pathways when patients received concomitant treatment with Taltz plus Zepbound for both conditions. These data at the intersection of psoriasis and obesity highlight immunometabolic health as an important area for continued scientific research."

These data follow previously reported results from TOGETHER-PsO, which showed that Taltz and Zepbound used together delivered superior skin clearance and clinically meaningful weight reduction compared with Taltz alone at the Week 36 primary endpoint. Improvements were maintained or further improved through Week 52, with safety consistent with the known profile of each respective medicine.

About the TOGETHER-PsO trial
TOGETHER-PsO (NCT06588283) is a 52-week Phase 3b, randomized, multicenter, assessor-blinded, open-label study assessing the efficacy and safety of concomitant administration of Taltz and Zepbound compared with Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight (BMI ≥30 kg/m², or ≥27 to <30 kg/m²) with at least one additional weight-related comorbid condition. A total of 274 participants were randomized 1:1 to receive either Taltz alone or concomitantly with Zepbound, both administered subcutaneously. Patients in both arms received counseling on a reduced-calorie diet and increased physical activity. The primary endpoint is to assess the proportion of participants achieving both Psoriasis Area and Severity Index (PASI) 100 and ≥10% weight reduction at Week 36.

About Taltz (ixekizumab)
Taltz is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Taltz inhibits the release of pro-inflammatory cytokines and chemokines. Taltz is approved to treat adults with active psoriatic arthritis and adults and children 6 years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Additionally, Taltz is approved for adults with active ankylosing spondylitis, and adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation.

About Zepbound (tirzepatide) injection
Zepbound (tirzepatide) is the first and only dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity medication. Zepbound tackles an underlying cause of excess weight. It reduces appetite and how much you eat. Zepbound is indicated for adults with obesity, or some adults who are overweight and also have at least one weight-related medical problem, to lose weight and keep it off. Additionally, Zepbound is FDA-approved to treat adults with moderate-to-severe obstructive sleep apnea and obesity. Zepbound should be used with a reduced calorie diet and increased physical activity. 

TALTZ INDICATIONS AND SAFETY SUMMARY
Taltz® (tȯl-ts) is an injectable medicine used to treat:

People 6 years of age and older with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy). Adults with active psoriatic arthritis. Adults with active ankylosing spondylitis. Adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. It is not known if Taltz is safe and effective in children for conditions other than plaque psoriasis or in children under 6 years of age.

Warnings - Taltz affects the immune system. It may increase your risk of infections, some people have had serious infections, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized from these infections. Do not use Taltz if you have any symptoms of infection, unless your doctor tells you to. If you have a symptom after starting Taltz, call your doctor right away.

Your doctor should check you for TB before you start Taltz, and watch you closely for signs of TB during and after treatment with Taltz. If you have TB, or had it in the past, your doctor may treat you for it before you start Taltz.

Do not use Taltz if you have had a serious allergic reaction to ixekizumab or any other ingredient in Taltz, such as: swelling of your eyelids, lips, mouth, tongue or throat, trouble breathing, feeling faint, throat or chest tightness, or skin rash. Get emergency help right away if you have any of these reactions. See the Medication Guide that comes with Taltz for a list of ingredients.

Severe skin reactions that look like eczema can happen during treatment with Taltz from days to months after your first dose and can sometimes lead to hospitalization. Your doctor may temporarily stop treatment with Taltz if you develop severe skin reactions. Tell your doctor if you have any of the following: redness or rash, itching, patches, your skin is dry or feels like leather, blisters or abrasions that ooze or become crusty, small bumps or plaques with scale or crusting.

Crohn's disease or ulcerative colitis (inflammatory bowel disease) can start or get worse with Taltz use. Tell your doctor if you have any of these symptoms or if they get worse: stomach pain, diarrhea, and weight loss.

You should not get live vaccines while taking Taltz. You should get the vaccines you need before you start Taltz.

Common side effects
The most common side effects of Taltz include:

Injection site reactions Nausea Upper respiratory infections Fungal skin infections Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before using
Before you use Taltz, review these questions with your doctor:

Are you being treated for an infection? Do you have an infection that does not go away or keeps coming back? Do you have TB or have you been in close contact with someone with TB? Do you have possible symptoms of an infection such as fever, cough, sores, diarrhea, or other symptoms? Ask your doctor about other possible symptoms. Do you have Crohn's disease or ulcerative colitis? Tell your doctor if:

You need any vaccines or have had one recently. You take prescription or over-the-counter medicines, vitamins, or herbal supplements. You are pregnant or planning to become pregnant. It is not known if Taltz can harm an unborn baby. Pregnancy Exposure Registry: There is a pregnancy registry to collect information about women who are exposed to Taltz during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. If you become pregnant while taking Taltz, you are encouraged to enroll in the pregnancy registry by calling 1-800-284-1695 or by visiting online at http://www.pregnancyregistry.lilly.com. You are breastfeeding or planning to breastfeed. It is not known if Taltz passes into breastmilk. How to take
See the instructions for use that come with Taltz. There you will find information about how to store, prepare, and inject Taltz. Adults may self-inject after receiving training from a healthcare provider.

For children 6 to 17 years of age:

If your child's healthcare provider decides that you may give Taltz injections at home, you should receive training on the right way to prepare and inject Taltz. Do not try to give Taltz to your child until you have been shown how to inject Taltz. Children should not inject themselves with Taltz. You or an adult caregiver should prepare and give Taltz injections to your child. Learn more
Taltz is a prescription medicine available as a 80 mg/mL, 40 mg/0.5mL, 20 mg/0.25mL injection. For more information, call 1-800-545-5979 or go to taltz.lilly.com.

This summary provides basic information about Taltz but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Taltz and how to take it. Your doctor is the best person to help you decide if Taltz is right for you.

IX CON BS 20AUG2024

U.S. ZEPBOUND INDICATIONS AND SAFETY SUMMARY WITH WARNINGS
Zepbound® (ZEHP-bownd) is an injectable prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with:

obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.

Warnings - Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound. KwikPen®: Do not share your KwikPen with other people, even if the pen needle has been changed. You may give other people a serious infection or get a serious infection from them.

Zepbound may cause serious side effects, including:

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Gallbladder problems. Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. You may feel the pain from your abdomen to your back.

Serious allergic reactions. Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin. 

Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Zepbound.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Zepbound may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures.

Common side effects
The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before using Zepbound

Your healthcare provider should show you how to use Zepbound before you use it for the first time. Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea. If you take birth control pills by mouth, talk to your healthcare provider before you use Zepbound. Birth control pills may not work as well while using Zepbound. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after each increase in your dose of Zepbound. Review these questions with your healthcare provider:
❑ Do you have other medical conditions, including problems with your pancreas, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑ Do you take diabetes medicines, such as insulin or sulfonylureas?
❑ Do you have a history of diabetic retinopathy?
❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?
❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. Zepbound may pass into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound.

Pregnancy Exposure Registry: There is a pregnancy exposure registry for women who have taken Zepbound during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may call 1-844-524-0039 or email at [email protected] or visit https://pregnancyregistry.lilly.com/zepbound. How to take

Read the Instructions for Use that come with Zepbound. Use Zepbound exactly as your healthcare provider says. Use Zepbound with a reduced-calorie diet and increased physical activity. Inject Zepbound under the skin (subcutaneously) of your stomach (abdomen), thigh, or
have another person inject in the back of the upper arm. Do not inject ZEPBOUND into a muscle (intramuscularly) or vein (intravenously). Use Zepbound 1 time each week, at any time of the day. Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection. If you take too much Zepbound, call your healthcare provider, call the Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

Zepbound is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg injection.

Learn more
Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979) or go to www.zepbound.lilly.com.

This summary provides basic information about Zepbound but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Zepbound and how to take it. Your healthcare provider is the best person to help you decide if Zepbound is right for you.

ZP CON BS 01SEP2026

Zepbound®, its delivery device base and KwikPen® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn.  P-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Taltz (ixekizumab) as a treatment for psoriasis and Zepbound (tirzepatide) as a treatment for adults with obesity or overweight, and potential comprehensive treatment strategies for patients with psoriasis and obesity, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development and commercialization. Among other things, there is no guarantee that future study results will be consistent with the results to date, or that Lilly will execute its strategies as planned. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

References and endnotes

Armstrong et al, Addressing the Obesity-Psoriasis Connection: Prevalence, Incidence, and Comorbidity Insights from a Large US Population of 19.9 Million (2018-2024). Presented at Maui Derm, 2026. SOURCE Eli Lilly and Company

GAMMA Investing LLC grew its holdings in Dell Technologies Inc. (NYSE:DELL – Free Report) by 7.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,846 shares of the technology company’s stock after buying an additional 925 shares during the period. GAMMA Investing LLC’s holdings in Dell Technologies were worth $6,911,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Collective Family Office LLC boosted its position in Dell Technologies by 1.5% during the third quarter. Collective Family Office LLC now owns 1,299 shares of the technology company’s stock worth $699,000 after acquiring an additional 19 shares during the last quarter. Cornerstone Financial Management LLC raised its holdings in Dell Technologies by 56.1% in the 2nd quarter. Cornerstone Financial Management LLC now owns 64 shares of the technology company’s stock valued at $28,000 after acquiring an additional 23 shares during the last quarter. Noble Wealth Management PBC raised its holdings in Dell Technologies by 113.6% in the 3rd quarter. Noble Wealth Management PBC now owns 47 shares of the technology company’s stock valued at $25,000 after acquiring an additional 25 shares during the last quarter. Retirement Wealth Solutions LLC lifted its stake in Dell Technologies by 41.3% in the 3rd quarter. Retirement Wealth Solutions LLC now owns 89 shares of the technology company’s stock worth $48,000 after purchasing an additional 26 shares in the last quarter. Finally, Triumph Capital Management boosted its holdings in shares of Dell Technologies by 2.3% during the 2nd quarter. Triumph Capital Management now owns 1,405 shares of the technology company’s stock worth $606,000 after purchasing an additional 32 shares during the last quarter. 76.37% of the stock is owned by hedge funds and other institutional investors.

Dell Technologies Price Performance Shares of NYSE DELL opened at $575.17 on Friday. The company has a market capitalization of $365.70 billion, a P/E ratio of 33.38, a P/E/G ratio of 0.60 and a beta of 1.37. The company has a 50 day simple moving average of $504.43 and a 200-day simple moving average of $379.92. Dell Technologies Inc. has a 1 year low of $110.22 and a 1 year high of $595.51.

Dell Technologies (NYSE:DELL – Get Free Report) last released its quarterly earnings data on Tuesday, September 1st. The technology company reported $7.04 EPS for the quarter, beating analysts’ consensus estimates of $4.91 by $2.13. The firm had revenue of $46.97 billion for the quarter, compared to analysts’ expectations of $44.89 billion. Dell Technologies had a negative return on equity of 578.85% and a net margin of 7.53%.The firm’s quarterly revenue was up 57.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.70 earnings per share. Dell Technologies has set its FY 2027 guidance at 25.500-25.500 EPS and its Q3 2027 guidance at 6.500-6.500 EPS. As a group, research analysts expect that Dell Technologies Inc. will post 25.13 EPS for the current year. Dell Technologies Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Tuesday, October 20th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Tuesday, October 20th. Dell Technologies’s dividend payout ratio is 14.63%.

Analyst Ratings Changes A number of equities research analysts have recently issued reports on the company. Royal Bank Of Canada began coverage on Dell Technologies in a research report on Thursday, September 10th. They issued an “outperform” rating and a $640.00 price target for the company. Weiss Ratings reissued a “buy (b)” rating on shares of Dell Technologies in a research note on Wednesday, August 12th. Morgan Stanley upped their target price on Dell Technologies from $499.00 to $511.00 and gave the company an “equal weight” rating in a report on Monday, September 21st. Melius Research raised their target price on Dell Technologies from $650.00 to $735.00 and gave the stock a “buy” rating in a research note on Wednesday, September 2nd. Finally, Fox Advisors upgraded Dell Technologies from an “equal weight” rating to an “overweight” rating and set a $625.00 price target on the stock in a report on Wednesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-seven have issued a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $571.12.

Read Our Latest Research Report on DELL

Dell Technologies News Roundup Here are the key news stories impacting Dell Technologies this week:

Positive Sentiment: Dell received a bullish catalyst from an analyst upgrade: Mizuho raised its price target to $650 from $600 while maintaining an Outperform rating. The revision reflects reported AI-server orders of $60.9 billion, $16.4 billion in AI-server revenue and a $95 billion backlog. Why Dell Stock Is Trading Up Today Positive Sentiment: Dell launched new Windows PCs and workstations designed for “agentic AI” in collaboration with NVIDIA and Microsoft. The products expand Dell’s AI offerings beyond data-center servers and could support demand from developers and creative professionals. Dell Technologies Drives the Agentic AI Era Positive Sentiment: Coverage continues to highlight Dell’s expanding AI customer base, large backlog and recently enhanced AI Data Platform, including NVIDIA-powered acceleration, data orchestration and enterprise knowledge-graph capabilities. These developments reinforce the long-term AI infrastructure growth narrative. Can Dell Turn Its New AI Data Platform Into a Durable Competitive Advantage? Neutral Sentiment: CEO Michael Dell’s involvement in Trump Accounts and a pledge to fund accounts for children has increased the company’s visibility, but the initiative is philanthropic and does not directly change Dell’s operating outlook. Michael Dell Defends Trump Accounts Negative Sentiment: Several Silver Lake-affiliated directors sold a combined roughly 127,000 Dell shares for about $73 million on October 6. Multiple transactions reduced their holdings by approximately 68%–72%, creating a near-term supply and confidence overhang, although one seller retained a substantial position. SEC insider-trading filing Negative Sentiment: After a steep AI-driven rally, profit-taking across server stocks—including Dell and Hewlett Packard Enterprise—has encouraged investors to question whether the sector’s momentum can continue. Dell’s elevated valuation makes it more vulnerable to consolidation despite strong earnings and guidance. Profit Taking Unwinds Server Rally Insiders Place Their Bets In other Dell Technologies news, Director Silver Lake Partners Iv, L.P. sold 91,191 shares of the stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $517.34, for a total transaction of $47,176,751.94. Following the completion of the transaction, the director owned 64,209 shares of the company’s stock, valued at $33,217,884.06. This trade represents a 58.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Spv-2 L.P. Sl sold 83,006 shares of Dell Technologies stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $517.34, for a total transaction of $42,942,324.04. Following the sale, the director owned 73,185 shares of the company’s stock, valued at approximately $37,861,527.90. This represents a 53.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 1,697,272 shares of company stock valued at $920,162,797. Company insiders own 41.50% of the company’s stock.

(Free Report)

Dell Technologies Inc (NYSE: DELL) is a global technology company that develops, sells and supports information technology hardware, software and services. Its offerings include personal computers, workstations, monitors, accessories and other client devices, as well as enterprise infrastructure products such as servers, storage systems, networking equipment and data protection solutions.

The company also provides technology consulting, support, managed services and infrastructure solutions designed to help organizations operate data centers, private and hybrid clouds, artificial intelligence workloads and digital workplaces.

Featured Articles Five stocks we like better than Dell Technologies Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push

Receive News & Ratings for Dell Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dell Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Donald Trump spent much of 2026 publicly praising Dell, but newly disclosed transactions show investments held in his name were later reduced after the stock’s extraordinary AI-driven rally.

A federal ethics disclosure released Thursday showed one of his independently managed accounts sold between $500,001 and $1 million of Dell Technologies shares on August 21, followed by another $15,001-$50,000 sale on August 28.

The trades came months after Trump repeatedly urged Americans to “go out and buy a Dell computer”.

There is no evidence Trump personally directed either sale. The White House says third-party financial institutions manage his portfolio independently, while the Trump Organization says Trump and his family do not select or approve individual trades.

Trump’s portfolio bought between $1 million and $5 million of Dell shares on February 10. Nine days later, during remarks in Rome, Georgia, he praised Michael and Susan Dell and told the audience to “go out and buy a Dell computer”.

He repeated it at a July 6 White House event linked to Trump Accounts.

However, by August, Dell had become one of 2026’s biggest stock-market winners. The new filing shows the portfolio sold $500,001-$1 million of Dell on August 21 and another $15,001-$50,000 a week later.

That sequence is striking, but it is not evidence of a personally directed trade.

White House spokesperson Davis Ingle told Reuters that “all investment decisions are made entirely by independent managers”.

The relevant contrast is therefore between Trump’s public praise and the activity of outside portfolio managers.

The sales also make more sense against Dell’s share-price move.

Dell closed at $574.55 on Thursday, leaving the stock up about 356% in 2026. That gain reflects a dramatic rerating as AI infrastructure demand transformed expectations for the company’s server business.

Dell’s latest quarter underscored why. The company booked $60.9 billion of AI-server orders, recognised $16.4 billion of AI-server revenue and exited the period with a record $95 billion backlog. Management raised its full-year AI-server revenue forecast to $74 billion.

Yet valuation has become harder to ignore after such a rapid move.

Morgan Stanley analyst Erik Woodring described enterprise hardware spending as “undeniably strong” and said Dell was “clearly out-executing” competitors. Even so, Morgan Stanley kept an Equal Weight rating and a $511 price target.

Also read: Trump bought up to $5M SpaceX debt days before signing new space policy

Mizuho analyst Vijay Rakesh this week raised his Dell target to $650 from $600 and maintained an Outperform rating, arguing that “agentic AI adoption is accelerating”.

The view is that new AI workloads should keep supporting demand for servers and related infrastructure.

TD Cowen is more cautious. Analyst Krish Sankar raised his target to $550 from $500 but kept a Hold rating, highlighting Dell’s $95 billion AI-server backlog while warning that memory constraints could become a risk in 2027.

The broader consensus remains positive, but targets are increasingly clustering around the current share price after this year’s surge.

Cars queue to refuel at a Lukoil fuel station in Moscow, Russia, August 17, 2026. REUTERS/Anastasia Barashkova/File Photo Purchase Licensing Rights, opens new tab

CompaniesLONDON, Oct 9 (Reuters) - US private equity firm Carlyle Group (CG.O), opens new tab said on Friday it was no longer actively pursuing ​a deal to acquire international assets of ‌Russia's second-largest oil producer Lukoil (LKOH.MM), opens new tab, a spokesman for the firm said.

The group did not comment further.

Sign up here.

The assets ​were put up for sale last ​year following sanctions imposed by the United ⁠States over Russia's war in Ukraine. Another ​Russian oil major, Rosneft (ROSN.MM), opens new tab, was also sanctioned, but ​it has not announced any divestments.

Carlyle had initially agreed on January 29 to buy Lukoil's assets, excluding those in ​Kazakhstan. The fund was in talks to ​partner with Abu Dhabi-based funds Mubadala, XRG and IHC, ‌as ⁠well as the US Development Finance Corporation for the deal, according to people familiar with the matter.

The Lukoil portfolio, initially valued at around $22 ​billion, had ​attracted interest ⁠from at least a dozen companies including Exxon Mobil (XOM.N), opens new tab and the former ​owner of Pornhub, Bernd Bergmair.

The Financial ​Times reported ⁠last month that US billionaire businessman Todd Boehly secured the backing of the US government and Gulf power ⁠brokers ​with ties to Donald ​Trump's family to bid for Lukoil's international assets.

Reporting by Shadia ​Nasralla; writing by Vladimir Soldatkin;Editing by Elaine Hardcastle

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Prefer us on Google

Summary:

AUD/JPY retested the 110.50 level after securing four daily gains, driven by renewed appetite for risk-sensitive assets and technical buying. Cautious Bank of Japan communications reduced near-term rate hike expectations, while sticky Australian inflation keeps RBA rate hike risks plausible. Key risks that could reverse gains include stronger Japanese data, hawkish BoJ signals, weaker commodities or a broad risk-off move favouring the yen. The AUD/JPY currency pair has fluctuated this week. The Australian dollar gained against the Japanese yen in four of the last six trading sessions, and after two straight declines, AUD/JPY approached the 110.50 level during the Asian trading session.

Is this recent upward movement a sustained recovery, or just a temporary pause before a potential decline?

Why Buyers Are Returning Signals from the Bank of Japan (BoJ) are bringing buyers back. Even though the BoJ hiked interest rates in September, markets found its guidance less aggressive than expected.

Comments from Governor Ueda on Tuesday and statements from board member Ayano Sato, who advocated for a gradual approach to monetary policy tightening, suggest that borrowing the yen may remain inexpensive for now.

Markets now price in a much lower chance of an October rate hike from the BoJ, now around 12% compared to last week’s 40%. This shift has lowered immediate demand for the yen, potentially prompting carry traders to rebuild long positions in the Australian dollar.

Australia’s higher interest rate differential also provides ongoing fundamental support for the Australian dollar. The Reserve Bank of Australia (RBA) has kept a tighter monetary policy than the BoJ, which gives the Australian dollar a yield advantage.

Is the Upside Momentum Sustainable? This upside momentum, however, needs more confirmation to prove sustainable. While buyers did push the pair back above the 110.00 psychological level, it’s still below its 100-day Simple Moving Average (SMA) near 112.45.

Short-term technical indicators, like the Relative Strength Index (RSI) on lower timeframes, look overbought. For this uptrend to continue, we’d need a clear daily close above 111.00.

Fundamentally, the interest rate differential and the BoJ’s cautious stance offer some support. But these gains will need ongoing confirmation to stick.

If Japanese monetary policy stays gradual and Australian economic data holds up, the pair might extend its recent climb. Yet, the broader technical picture suggests sellers could keep pushing down on rallies until it breaks past key moving averages.

Potential Disruptors Ahead Several factors could disrupt the current rebound. Any hint of a more hawkish shift from the BoJ or stronger Japanese economic data could reignite rate hike expectations and strengthen the yen.

Reports suggest President Trump discussed concerns about yen weakness with Prime Minister Takaichi, sparking talk of a possible joint US-Japan intervention. This kind of intervention would directly oppose yen weakness, and it could happen with little warning.

On the Australian side, given Australia’s heavy reliance on raw material exports to China, any unexpected weakening in Chinese manufacturing or industrial output would hurt the Australian dollar.

A general move towards risk aversion in global markets also often sends investors to the yen as a safe-haven, potentially pushing AUD/JPY lower. So, we’ll need to watch upcoming central bank meetings and key economic data releases closely.

What’s driving the recent buying interest in AUD/JPY?

Softer comments from the Bank of Japan have reduced the odds of an October rate hike to about 12%, weighing on the yen. Meanwhile, Australia’s higher yields continue to support the Australian dollar.

What could disrupt the current recovery?

The key factors that could disrupt recovery include  stronger Japanese economic data, more hawkish signals from the BoJ, weakness in commodity prices, or a broad move to risk aversion that strengthens the yen as a safe haven.

What’s the main technical resistance limiting AUD/JPY’s immediate gains?

The 100-day Simple Moving Average near 112.45 is a significant overhead resistance. It’s currently capping any bigger upward moves.

Samsung Wallet now supports USDC on the Sui blockchain for eligible Galaxy devices in the US, the Sui Foundation announced on October 8. The integration covers up to 82 million US Galaxy devices, with other markets to follow at an unspecified date.

Users can hold and send USDC directly within Samsung Wallet. USDC is the only asset supported at launch, and the SUI token is not available. Sui's gasless stablecoin transfers mean users pay no network fee and do not need to hold SUI to move dollars.

"Stablecoins have the potential to make moving money around the world faster and easier," said Woncheol Chai, head of the digital wallet team in Samsung Electronics' mobile business.

Adeniyi Abiodun, co-founder and chief product officer of Mysten Labs, the original contributor to Sui, said that "stablecoins have proven that dollars can move globally in seconds."

The announcement settles details Samsung left open in July, when it showed a Samsung Wallet mockup holding USDC at its Galaxy Unpacked event in London but gave no chain, issuer or launch date. Choosing Sui over Ethereum, Solana or Base hands a high-profile distribution win to a network that has been courting payments use cases. Sui says it has processed more than $1 trillion in stablecoin transfer volume since August 2025.

Several practical questions remain. The announcement does not say how users fund their USDC balance, whether through a bank, a card or an exchange integration, or whether the wallet is self-custodial. It also describes the feature in terms of sending money and remittances, with no mention of paying merchants through Samsung Pay, which is where a phone wallet's distribution would matter most. Circle is not named as a partner, although native USDC has been live on Sui since 2024.

The 82 million figure measures potential reach. How many Galaxy owners actually fund a USDC balance will depend largely on the on-ramp, which Samsung and Sui have yet to describe.

2 min read

New bitcoin lending system is set to debut. (Shubham Dhage/Unsplash)Summary

Layer-1 blockchain Sui is launching Hashi, an institutional protocol allowing holders to use Bitcoin as collateral without moving it off the Bitcoin network.The system is debuting with $500 million in capital commitments from a coalition of over 20 industry partners to ensure deep day-one liquidity.Hashi’s mainnet will roll out in phases, targeting a massive pool of roughly $1 trillion in dormant, institutional Bitcoin.Bitcoin BTC$82,582.92-backed finance is about to get a massive, well-funded liquidity boost.

Layer-1 blockchain Sui is set to launch Hashi, a new institutional network that allows holders to use Bitcoin as collateral for lending without moving it off the Bitcoin ledger. The mainnet is slated to roll out in phases later this month.

To back the ecosystem, the initiative has already secured $500 million in capital commitments from a coalition of over 20 industry partners.

While these are commitments rather than immediate deposits, the pre-pledged capital ensures that when the system debuts, markets can open with deep liquidity instead of starting empty.

“Hashi is launching with serious capital and a coalition of industry leaders because institutions want to put Bitcoin to work without giving up the protections they require,” Adeniyi Abiodun, Co-Founder and Chief Product Officer of Mysten Labs, the original creator of Sui, said in an official announcement.

The primary target for this capital is a massive pool of dormant wealth. Sui estimates that roughly $1 trillion worth of Bitcoin is currently sitting idle. Until now, institutional and corporate balance-sheet holders have lacked a compliant, transparent ecosystem to safely deploy their native Bitcoin in decentralized finance (DeFi).

This launch comes amid a broader shift in Bitcoin-backed finance, where borrowing is moving far beyond speculative crypto trading. Bitcoin holders now use bitcoin-collateralized loans to cover real-world expenses like university tuition, real estate acquisitions, and corporate working capital.

"Public companies and institutions hold enormous amounts of Bitcoin, but their ability to use that capital has been constrained by the technology available to them," said Nathan McCauley, CEO and co-founder of Anchorage Digital, a day-one launch partner that also plans to supply stablecoin liquidity to the network.

"Connecting our institutional clients with Hashi represents a complete paradigm shift,” McCauley added.

Here’s how the system overcomes these institutional constraints. Instead of bridging across blockchains, users securely lock their BTC in a vault address directly on the Bitcoin blockchain. A 2-of-2 multisig secures this address, requiring cryptographic sign-off from both Hashi’s validators. Hashi also has a separate, independent guardian layer designed to monitor and slow suspicious collateral movements.

While the real bitcoin stays safely frozen on the Bitcoin network, Hashi mints hBTC, a digital voucher token on Sui, backed directly by that deposit. This is where the lending action begins. Apps on Sui can use these hBTC vouchers to fuel lending, borrowing, credit markets, and real-world asset trading. When a user wants to exit, the hBTC voucher is permanently burned on Sui, which triggers the multisig to safely unlock and release the original bitcoin back to the user on the Bitcoin network.

To meet strict institutional compliance and security standards, Hashi has undergone rigorous vetting. Security firm Certora formally verified Hashi's smart contracts, while another firm, CommonPrefix, reviewed the cryptography of its multi-party computation (MPC) protocol.

AI Disclaimer: Parts of this article were generated with the assistance from AI tools and reviewed by our editorial team to ensure accuracy and adherence to our standards. For more information, see CoinDesk's full AI Policy.

Related Assets

12345678910The Definitive Stablecoin Landscape Series: Asia Pacific

The Definitive Stablecoin Landscape Series: Asia Pacific

As stablecoins move into regulated finance, APAC is becoming a key proving ground. This report maps the region’s rules, use cases, and RLUSD’s role.

Sep 15, 2026

As stablecoins move into regulated finance, APAC is becoming a key proving ground. This report maps the region’s rules, use cases, and RLUSD’s role.

Why it matters:

As stablecoins move into regulated finance, APAC is becoming a key proving ground. This report maps the region’s rules, use cases, and RLUSD’s role.

As I write, Coca-Cola (KO +2.27%) stock would need to climb about 14% from roughly $88 to hit $100 a share. The shares have already risen about 26% this year, and they closed at a record of almost $92 in late August.

With the end of 2027 about 15 months away, the climb works out to about 11% a year in price alone. A dividend yielding about 2.4% at the stock's current price comes on top of that.

For a company whose organic revenue (sales growth excluding currency moves, acquisitions, and divestitures) rose 5% last year, 11% a year is arguably a fast pace. But I think the stock can get there, if earnings keep growing at their recent rate.

Image source: The Motley Fool.

Where did this year's rise come from?Mainly from a higher valuation. Coca-Cola stock closed 2025 around $70. Against its 2025 non-GAAP (adjusted) earnings per share of $3.00, that was about 23 times earnings. Now, the stock trades at about 27 times adjusted earnings, using the $3.23 per share over its past four quarters.

In other words, adjusted earnings per share grew around 8% while the stock gained 26%. Most of the run-up comes from a higher price on every dollar of Coca-Cola's earnings, and I wouldn't count on another year like that.

So earnings have to carry most of the climb to $100. Management expects 2026 adjusted earnings per share of around $3.27 to $3.30, up 9% to 10%. But currency accounts for around 3 points of it. Leaving out currency and the effect of acquisitions and divestitures, the company expects growth of 7% to 8%.

If adjusted earnings per share rises around 7.5% again in 2027, it'd be near $3.53. If shares still fetch 27 times adjusted earnings then, that points to a stock price of around $96 by the end of 2027. Hitting $100 would take about 28 times adjusted earnings -- or a year of faster growth.

Coca-Cola is selling more drinksShowing how the mix of its growth has changed, Coca-Cola's unit case volume (the amount of its drinks sold in its system) dropped 1% from the year before in the second quarter of 2025. Since then, volume growth has sped up, to 1% in both the third and fourth quarters of 2025, then 3% to start 2026 and 5% in the latest quarter.

Price/mix (the combined impact of price moves and shifts in what drinks and packages sell, and where) went the other way. It slowed from 6% growth in mid-2025 to 2% in this year's second quarter. And organic revenue still rose 6% in the quarter.

I think volume-led growth is the healthier kind, since it doesn't rely on consumers absorbing ever-higher prices.

"[W]e said that this would be a year that if we did everything right, we would see volume and price/mix more in tandem," CEO Henrique Braun said on Coca-Cola's second-quarter earnings call. "And that's exactly what we're seeing."

Granted, management also credited the FIFA World Cup, favorable weather in some markets, and an easy comparison, leaving two-year average volume growth at 2%. But profitability rose, too. Coca-Cola's adjusted operating margin widened to 35.6% from 34.7% a year before.

Premium Feature

Moneyball Superscore

76/100

Today's Change

(

2.27

%) $

1.95

Current Price

$

87.77

What does Oct. 27 have to show?Coca-Cola releases third-quarter results before the opening bell on Tuesday, Oct. 27. Its full-year outlook points to adjusted earnings per share of about $1.44 to $1.47 for the second half, up only about 3% to 5%, partly because the fourth quarter has six fewer days than last year.

Volume is the figure I'd track most closely. Against 1% growth in the year-ago quarter, volume growth of roughly 3% would hold the two-year pace near 2%.

Price/mix counts, too. PepsiCo cut its 2026 outlook for adjusted, currency-neutral earnings-per-share growth to 1% to 2% on Thursday, and said it's lining up more cost cuts partly to offset rising input cost inflation. Coca-Cola noted higher input costs in its second quarter as well, so price/mix staying around 2% could show it can still price through them.

Will Coca-Cola stock clear $100 before 2028? I think so. If volume keeps rising near its two-year pace and pricing holds, earnings growth around 8% a year could carry the stock to the mid-$90s. And a stock that already reached $92 in August needs just a slightly higher valuation on top of that.

But this is a prediction about earnings growth more than a bargain price. At around 25 times projected 2027 earnings, shares already assume steady growth, and one or two quarters of slower volume could easily push $100 to 2028.

Innovative Industrial Properties Prices Public Offering of 9.25% Series B Cumulative Redeemable Preferred Stock Innovative Industrial Properties, Inc. (the “Company”) (NYSE: IIPR) announced today the pricing of an underwritten public offering of 2,000,000 shares of its 9.25% Series B Cumulative Redeemable Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”), at a price of $25.00 per share, for gross proceeds of $50,000,000. The Company granted the underwriters of the offering a 30-day option to purchase up to an additional 300,000 shares of the Company’s Series B Preferred Stock at the public offering price to cover overallotments, if any. The Company plans to file an application to list the Series B Preferred Stock on the New York Stock Exchange under the symbol “IIPR Pr B.” Shares of the Company’s common stock also trade on the New York Stock Exchange under the symbol “IIPR.” The offering is expected to close on October 19, 2026, subject to customary closing conditions.

Stifel is acting as active bookrunner for the offering. A.G.P./Alliance Global Partners, Huntington Capital Markets and Oppenheimer & Co. are acting as passive bookrunners for the offering, and Academy Securities, Clear Street, Compass Point, Roberts & Ryan, Roth Capital Partners and Wolfe Capital Markets and Advisory are acting as co-managers for the offering.

The Company intends to use the net proceeds from the offering to fund all or a portion of its remaining unfunded commitment under its previously announced mezzanine loan investment in the life science industry and to use any remaining net proceeds to fund investments consistent with its investment strategy and for general corporate purposes.

This offering is being made only by means of a written prospectus. A copy of the final prospectus related to the offering may be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate Department, 1201 Wills Street, Suite 600, Baltimore, MD 21231, or by email at [email protected].

The offering is being made pursuant to an effective automatic shelf registration statement on Form S-3 previously filed with the SEC on February 21, 2025. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Innovative Industrial Properties

Innovative Industrial Properties, Inc. is an internally managed real estate investment trust (REIT) focused on the acquisition, ownership and management of specialized properties leased to experienced, state-licensed operators for their regulated cannabis facilities and financial investments in the life science industry.

This press release contains statements that are “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical facts, including, without limitation, statements regarding the closing of the offering, the terms of the Series B Preferred Stock, and the use of proceeds from the offering, are forward-looking statements. When used in this press release, words such as the Company “believes,” “expects,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “plans,” “estimates” or “anticipates” or the negative thereof or similar terminology are generally intended to identify forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in, or implied by, such statements. Investors should not place undue reliance upon forward-looking statements. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261008729556/en/

Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.

Click for the complete disclosure

GBP/USD rose to 1.3237 on Friday. Following a rapid decline, the pound has entered a consolidation phase, although the main external drivers remain a strong US dollar and a renewed rise in bond yields amid inflation risks.

The focus remains on Bank of England policy. Markets put the probability of a rate hike at the November meeting at over 80% and are effectively pricing in two 25-basis-point hikes by February. High energy prices and concerns that inflationary pressures in the UK could prove more persistent are reinforcing these expectations. MPC member Megan Greene also warned that the Bank of England should not rely solely on high bond yields as a means of curbing inflation.

During his speech in Istanbul, Andrew Bailey focused less on the next rate decision and more on financial stability and fiscal policy. He stressed the need for a credible and predictable fiscal strategy amid soaring borrowing costs. UK government bond yields are near multi-year highs, increasing pressure on the budget and making the pound more sensitive to any signs of deteriorating fiscal discipline.

As a result, the fundamental backdrop for sterling remains mixed. Expectations of further Bank of England tightening support the currency, but a strong US dollar, elevated global yields and rising UK fiscal risks are limiting GBP/USD’s upside. In the short term, the balance will depend on whether expectations of a BoE rate hike can outweigh pressure from the US dollar.

Technical Analysis

On the H4 chart, GBP/USD remains in the downtrend that developed after the upward correction ended. The pair attempted to recover towards resistance at 1.3250 but failed to establish a foothold above it. The current structure suggests that the corrective move may be nearing completion, with the main downward move poised to resume.

In today’s trading session, the pair is expected to decline towards the nearest support at 1.3185. A confirmed break below this level would set up a third Elliott wave, followed by a move towards 1.3118 and 1.3108. The MACD indicator provides further confirmation of the bearish scenario and remains in negative territory. Despite the local recovery in the histogram, the indicator’s position does not yet signal a full reversal of the medium-term trend.

On the H1 chart, GBP/USD appears to be in the final stage of its upward correction around 1.3250. This resistance coincides with the descending trend line, increasing the likelihood of renewed selling. The Stochastic oscillator has turned down from elevated levels, signalling weakening buying momentum.

The main scenario remains a decline towards 1.3180, followed by a further move towards 1.3104. Intermediate levels are 1.3201 and 1.3118. At the same time, a return above 1.3250 would weaken the current bearish scenario and open the way for a retest of resistance at 1.3303.

Conclusion GBP/USD has steadied after a sharp decline, although the outlook remains mixed as the pound contends with a strong US dollar, elevated bond yields and rising UK fiscal risks. Markets continue to price in further Bank of England tightening, with the probability of a November rate hike above 80% and two 25-basis-point hikes effectively priced in by February, supported by persistent inflation concerns. However, Andrew Bailey’s focus on fiscal sustainability and financial stability, rather than the next rate decision, highlights the broader challenges facing the UK economy. Technically, the pair remains bearish below 1.3250, with a decline towards 1.3185 and potentially 1.3104 if support breaks. A recovery above 1.3250 would ease pressure but would not alter the broader downtrend, with 1.3303 as the next key resistance level.

ActionForex

ActionForex.com was set up back in 2004 with the aim to provide insightful analysis to forex traders, serving the trading community for two decades. We started providing only a daily and a mid-day report, now known as Action Insights. Gradually, we added a lot more in-house contents to the site. Technical Outlook section was expanded to cover more pairs. In addition to that, Top Movers, Heat Map, Pivot Point Charts and Pivot Meters, Action Bias and Volatility Charts, are tools used by traders from all over the world.

Dünyanın en büyük kripto para borsalarından Binance, iki altcoin hakkında yatırımcıları yakından ilgilendiren önemli bir karar açıkladı. Borsa, 9 Ekim 2026 itibarıyla Biconomy (BICO) ve Civic (CVC) tokenlerini İzleme Etiketi (Monitoring Tag) listesine ekleyeceğini duyurdu. Bu gelişme, söz konusu altcoinlerin ilerleyen süreçte platformdan delist edilme ihtimalini gündeme getirirken yatırımcıların dikkatini Binance’in değerlendirme sürecine çevirdi.

Binance Futures (Vadeli İşlemler) %10 İndirimli İşlem Yapmak İçin Tıkla!

Binance BICO ve CVC İçin İzleme Kararı Aldı Binance tarafından yayımlanan resmi duyuruya göre Biconomy (BICO) ve Civic (CVC), 9 Ekim 2026 tarihinden itibaren Monitoring Tag kapsamına alınacak. Borsa, gerçekleştirdiği son incelemeler sonucunda iki altcoinin daha yakından takip edilmesine karar verdi. İzleme Etiketi, Binance’in belirlediği kriterler doğrultusunda daha yüksek risk taşıdığı değerlendirilen kripto varlıkları işaret ediyor. Bu nedenle BICO ve CVC yatırımcılarının, borsadan gelecek yeni açıklamaları yakından takip etmesi önem taşıyor.

Binance’in Monitoring Tag uygulaması, diğer listelenmiş tokenlere kıyasla daha yüksek volatilite ve risk taşıyabilen kripto para birimlerini belirlemek amacıyla kullanılıyor. Bu etikete sahip projeler, borsa tarafından düzenli olarak inceleniyor ve listeleme standartlarına uygunlukları değerlendiriliyor. Ancak bir tokenin izleme listesine alınması, doğrudan delist edildiği anlamına gelmiyor. Bununla birlikte Binance’in gerekli koşulların karşılanmadığını belirlemesi halinde ilgili tokenin platformdan kaldırılması gündeme gelebiliyor.

BICO ve CVC Fiyatları Nasıl Etkilenebilir? Biconomy (BICO) ve Civic (CVC) tokenlerinin Binance izleme listesine eklenmesi, yatırımcıların risk algısını etkileyebilecek önemli bir gelişme olarak değerlendiriliyor. Özellikle delist ihtimalinin gündeme gelmesi, söz konusu altcoinlerde kısa vadeli fiyat dalgalanmalarını ve işlem hacmindeki değişimleri artırabilir. Ancak bu kararın kesin olarak satış baskısına neden olacağını söylemek mümkün değil. Yatırımcılar, BICO ve CVC fiyatlarının yanı sıra piyasa likiditesini ve Binance’in gelecekte yayımlayacağı değerlendirme sonuçlarını takip ediyor.

Binance’in son açıklaması, BICO ve CVC tokenlerinin doğrudan platformdan kaldırılacağı anlamına gelmiyor. Borsa, her iki projeyi de izleme sürecine dahil ederek listeleme kriterlerine uygunluklarını değerlendirmeye devam edecek. Projelerin geliştirme faaliyetleri, işlem hacimleri, likidite koşulları ve diğer listeleme standartları bu süreçte önem taşıyor. Binance’in ilerleyen dönemde yapacağı değerlendirmeler sonucunda izleme etiketleri kaldırılabileceği gibi gerekli kriterlerin karşılanmaması halinde delist kararı da alınabilir.

Değerlendirme Binance’in Biconomy (BICO) ve Civic (CVC) tokenlerini Monitoring Tag listesine eklemesi, iki altcoin açısından dikkatle takip edilmesi gereken bir gelişme olarak öne çıkıyor. Karar henüz kesin bir delist işlemi anlamına gelmese de yatırımcıların olası riskleri değerlendirmesi önem taşıyor. Önümüzdeki süreçte Binance’in resmi açıklamaları ve projelerin listeleme kriterlerine uyumu, BICO ve CVC’nin borsadaki geleceği açısından belirleyici olacak.

Son Dakika kripto para haberleri için hemen tıkla.

Konu ile ilgili yorumlarınızı bize yazabilirsiniz. Ayrıca, bu tarz bilgilendirici içeriklerin devamının gelmesini isterseniz, bizleri Telegram, Youtube ve Twitter kanallarımızdan takip edebilirsiniz.

Duolingo, Inc. Notice of December 7, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Duolingo, Inc. (NasdaqGS: DUOL) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors who purchased Duolingo, Inc. Class A common stock between May 2, 2025 and February 26, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Pennsylvania.

Follow the link below to get more information and be contacted by a member of our team:

https://www.ksfcounsel.com/cases/nasdaqgs-duol/

Duolingo investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3615 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-duol/ to learn more.

>>>CLICK HERE for more information

CASE DETAILS: According to the Complaint, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.

Specifically, the lawsuit alleges that Defendants failed to disclose to investors that: (i) Duolingo was deliberately adding friction to the user experience, through sharply increased ad volume, upselling of subscription tiers, and declining product quality, which Defendants knew would drive users away from the app and ultimately slow Daily Active User (“DAU”) growth; (ii) Duolingo’s extensive A/B testing showed Defendants that added friction in the free user experience was hurting DAU growth; (iii) Duolingo’s rapidly produced AI content was degrading its product offerings, harming the user experience and user trends, and putting the sustainability of Duolingo’s financial performance at risk; and (iv) rather than fueling sustained growth and strong user momentum through content and “product improvements” that “get improved retention,” Duolingo’s monetization push and lower-quality AI content were, as its ongoing A/B testing revealed, eroding both the product experience and the value of its subscription tiers.

The case is City of Dearborn Heights Act 345 Police & Fire Retirement System v. Duolingo, Inc., No. 26-cv-02199.

WHAT TO DO? If you invested in Duolingo and suffered a loss during the relevant time frame, you have until December 7, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

>>>To Learn More, Click HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

>>>For More Information about the case, Click HERE

View source version on businesswire.com: https://www.businesswire.com/news/home/20261008679615/en/

Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.

Click for the complete disclosure

The Pound-Euro rate could stay supported if French fiscal concerns persist, although rising UK gilt yields may limit Sterling’s upside. The Pound to Euro (GBP/EUR) exchange rate maintained a positive trajectory on Thursday, trading just below the 15-month high struck earlier in the week.

At the time of writing, the GBP/EUR exchange rate was trading at around €1.1806. A modest rise from the start of Thursday’s session.

Latest — Exchange Rates:

Pound to Euro (GBP/EUR): 1.180062 (+0.03%)

Pound to Dollar (GBP/USD): 1.322954 (+0.12%)

Euro to Dollar (EUR/USD): 1.121089 (+0.09%)

DAILY RECAP:

The Euro (EUR) continued to face resistance on Thursday as renewed concerns over European energy prices and France’s deteriorating fiscal position weighed on sentiment towards the single currency.

Brent crude climbed back above $104 a barrel amid fresh supply concerns, adding to inflationary pressures across the Eurozone and contributing to another rise in regional bond yields.

France remained at the centre of the market’s concerns as investors continue to question the sustainability of France’s €3.5tn debt burden and the government’s ability to rein in its sizeable budget deficit, particularly as its government is seen as unlikely to push its spending cuts through parliament.

The Pound (GBP) traded with modest support on Thursday following a speech by Bank of England (BoE) Governor Andrew Bailey.

While the bulk of his speech focused on his calls for financial markets to better prepare for future fiscal shocks, he also touched on the need for monetary policy to focus on controlling target.

Bailey warned that inflation risks are set to rise the longer that energy prices remain elevated and that the BoE is 'fully committed' to returning inflation to target.

Near-Term GBP/EUR Forecast: Rising UK Bond Yields to Sap Sterling? Turning to the end of the week, amid the ongoing turmoil in France investors are also likely to keep at least one eye on the UK bond market amid a continued rise in borrowing costs.

If Gilt yields continue to appreciate it's likely to raise fresh concern about the fiscal headroom available to Chancellor John Healey in his upcoming budget, and potentially apply pressure to the Pound Euro exchange rate.

Meanwhile, EUR investors will look to speeches by European Central Bank (ECB) policymakers for fresh impetus on Friday, with the Euro potentially catching bids if a hawkish consensus strengthens ECB rate hike expectations.

Exchange Rates UK Research Our currency coverage draws on live market data, official economic releases and published bank research.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Doximity (DOCS) To Contact Him Directly To Discuss Their Options

If you purchased or acquired Doximity common stock between August 8, 2024, and May 13, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648.

Click here to participate in the action.

NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) --

What’s Happening:

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Doximity, Inc. (“Doximity” or the “Company”) (NYSE:DOCS) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Doximity common stock between August 8, 2024, and May 13, 2026, both dates inclusive (the “Class Period”). Investors have until November 16, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Allegation Details:

The complaint alleges that during the Class Period defendants claimed the Company's Newsfeed was its "biggest revenue driver." Specifically, defendants claimed that the Company’s growth was “led by our Newsfeed, which is both our most used and most monetized product” and told investors that the Newsfeed was consistently “reach[ing] new highs,” with “an all-time record of quarterly active prescribers and double-digit growth in the number of articles read or tapped.” In addition, Doximity touted its “deep engagement,” assuring investors that Doximity does not “bombard physicians with ads and messages in hopes of getting lucky” and assured investors that “[Doximity does not] have an e-newsletter product.” In truth, Doximity overstated the impact that its Newsfeed had on its revenue growth, and the Company was losing market share to its competitors with more favorable pricing and engagement models. Additionally, notwithstanding its frequent statements to the contrary, Doximity relied heavily on both banner ads and email newsletters as advertising methods. Next Steps:

If you purchased or otherwise acquired Doximity shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
[email protected]
www.bespc.com

9.10.2026 09:14, BAACSG

Zbrojně-průmyslová skupina Czechoslovak Group (CSG) se přes společnost Federal Ammunition z americké muniční divize The Kinetic Group zapojila do vývoje autonomního protidronového systému SwarmShot. Partnery projektu jsou O.F. Mossberg & Sons a Palladyne AI. Cílem jsou opakovaně použitelné bezpilotní prostředky, které dokážou ve vzduchu vyhledávat a ničit nepřátelské drony, a to i v koordinovaném roji.

Projekt rozšiřuje aktivity CSG v oblasti pokročilých protidronových technologií. Kombinuje zkušenosti amerických společností skupiny s vývojem munice a autonomní systémy určené k obraně proti rychle se vyvíjejícím hrozbám spojeným s bezpilotními prostředky. Federal Ammunition do programu SwarmShot přináší zejména své know-how v oblasti speciální munice a zvyšování její účinnosti proti bezpilotním cílům.

„Federal dodává munici, která funguje jako efektor. Mossberg poskytuje zbraň. Palladyne AI zajišťuje dosah, inteligenci a koordinaci jednotlivých strojů,“ uvedl Ben Wolff, prezident a generální ředitel Palladyne AI. „Zásadní je, že všechny tři prvky vyvíjíme společně jako jeden celek.“

Včerejší zpráva vydaná v 17:06h doplněná o komentář analytika:

„Je to další zapojení CSG do odvětví nejmodernějších vojenských obranných technologií se zajímavým potenciálem do budoucna. V rámci nově utvářené sub-divize Advanced Systems CSG postupně vyvíjí aktivity související s bezpilotními prostředky, jako jsou například rozvoj vlastní výroby pohonných motorů do těchto prostředků nebo třeba kapitálový vstup do kanadské společnosti North Vector Dynamics vyvíjející pokročilé technologie protivzdušné obrany. CSG je tak již v tomto segmentu nejmodernějších bezpečnostních technologií zainteresována, je jeho součástí a postupně ho rozvíjí. Vytváří si tak další pilíř v rámci své skupiny, jenž může přinášet zajímavé synergie i pro své jádrové aktivity v segmentech konvenční pozemní vojenské techniky a munice,“ doplnil analytik Fio banky Jan Raška.

Zdroj: CSG

Michal Bárta
Fio banka, a.s.
Prohlášení

Nvidia (NVDA -2.94%) is highly unlikely to conduct a stock split in 2026, even after recently reaching a new all-time high. The leading chipmaker hasn't announced one, and its previous splits came when its share price was much higher.

It's usually not a good idea to wait for a company to split its stock before you invest. In Nvidia's case, you'd probably be waiting a very long time, and you'd be missing out on a quality company.

Image source: The Motley Fool.

Why an Nvidia stock split probably isn't happening in 2026 A few numbers make it clear why a stock split isn't on the horizon for Nvidia. The first is its share price. Companies usually split their stock to make it more affordable for retail investors. When Nvidia conducted its last stock split, a 10-for-1 split in 2024, it was trading at about $1,200. Before that, it conducted a 4-for-1 split in 2021 when it was trading at about $750.

Nvidia closed at $239 on Oct. 6. Its share price would need to be roughly three to five times larger to be in the same range as during its previous stock splits.

That brings us to the second important number: Nvidia's market cap of $5.8 trillion. If the company were to grow three times larger, it would have a market cap of more than $17 trillion. In all likelihood, Nvidia won't need to split its stock again for the rest of the decade.

Nvidia is set up well for continued growth One of the main reasons some investors are reluctant to buy Nvidia is its size. It already tops the list of the world's largest public companies, so there's the question of how much it can continue to grow from here.

But companies continue to spend heavily on artificial intelligence (AI), and Nvidia is reaping the benefits. It reported $96.2 billion in revenue in Q2 FY 2027, up 106% year over year, on an excellent gross margin of 75%. Most of that ($89 billion) is data center revenue, as Nvidia makes the most popular AI chips, including its Blackwell and Vera Rubin lines.

Premium Feature

Moneyball Superscore

95/100

Today's Change

(

-2.94

%) $

-6.99

Current Price

$

230.48

Even after Nvidia's recent growth, it's reasonably valued for one of the top AI stocks. It trades at about 26 times forward earnings and has a forward price/earnings-to-growth (PEG) ratio of less than 0.3. A PEG ratio below 1 indicates a company may be undervalued, and Nvidia is well below that mark.

Nvidia is doing the opposite of a split, and that's good news for investors A stock split increases a company's number of shares without changing the value of your position or your ownership stake. If a company trades at $500 and carries out a 5-for-1 split, each $500 share becomes five new $100 shares.

Nvidia, on the other hand, is buying back shares. On Sept. 28, the company announced that its board of directors authorized a $150 billion increase to its share repurchase program, increasing the program total to $235 billion. It expects to execute the total remaining through its fiscal 2028, essentially the next five quarters and change.

Buybacks are generally better for investors than stock splits because they reduce the number of outstanding shares. Each share has a larger ownership stake, and earnings per share (EPS) rise. The fact that Nvidia's board authorized a $150 billion increase suggests management considers the stock undervalued, and it's a large commitment to return capital to shareholders.

Nvidia's value isn't about the share price The real value of Nvidia is its crucial role in the AI build-out. Tech companies are investing in AI infrastructure, with the four largest hyperscalers (Alphabet, Amazon, Meta Platforms, and Microsoft) reporting over $300 billion of capital expenditures in the first half of 2026, according to research by The Motley Fool. Even with increased competition from Advanced Micro Devices and custom chipmakers, Nvidia still has an estimated 75% share of the AI accelerator market.

There are valid concerns about Nvidia. My primary worry is that it's heavily dependent on AI spending, and if companies slow down that spending, Nvidia's performance would suffer.

However, given how AI is progressing and its role as a potentially transformative technology, I expect the AI build-out to continue. If you're bullish on AI, then Nvidia is still worth considering as an investment, especially considering its growth and affordable valuation.

 | Source: Applied Materials, Inc.

R&D programs to focus on speeding up the commercialization pipeline so chip technology moves from breakthrough research to full-scale manufacturing fasterCollaborative work at the state-of-the-art facility in Silicon Valley pairs UCLA’s semiconductor research strength with Applied’s cutting-edge chipmaking equipment and process integration expertise SANTA CLARA, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Applied Materials, Inc. today announced that the UCLA Samueli School of Engineering will join the company’s EPIC Center in Silicon Valley as a research partner. Together with Applied’s scientists and engineers, UCLA researchers will work to solve semiconductor materials and integration challenges with a focus on shortening the time it takes to bring breakthrough research to commercialization.

“As the industry races to bring new AI chip technologies to market, the EPIC Center will play a pivotal role by convening the industry’s top innovators in a collaborative environment designed to accelerate the path from breakthrough research to full-scale manufacturing,” said Dr. Prabu Raja, President of the Semiconductor Products Group at Applied Materials. “UCLA has a long history of semiconductor technology innovation and Applied looks forward to welcoming their researchers to the EPIC Center where together we will work to solve the industry’s toughest challenges.”

The EPIC Center aims to accelerate chip R&D by bridging the gap between traditional academic innovation and industrial-scale development. UCLA researchers will have access to advanced chipmaking tools so that new ideas can be validated and tested in a commercial fab environment, thereby shortening the path from concept to production.

UCLA Samueli brings extensive expertise across semiconductor devices, materials, electronics and computing. In 1991, Henry Samueli co-founded Broadcom Corporation while teaching at UCLA. The school is also home to the Center for Heterogeneous Integration and Performance Scaling (CHIPS) Lab, which brings together researchers across disciplines to advance semiconductor technologies and address challenges in chip design, manufacturing and integration.

By collaborating at the EPIC Center, Applied Materials and UCLA will focus R&D programs on the semiconductor industry’s most critical challenges in areas including 3D chip scaling, advanced packaging and the discovery of new materials for improving energy-efficient AI compute performance. The work will complement and extend the efforts of UCLA’s Semiconductor Hub, which Applied joined as a co-founding member earlier this year. Applied’s ongoing commitment to strengthen the ties between industry and academia is aimed at empowering the next generation of engineers and researchers to bring semiconductor breakthroughs to market faster.

“Accelerating semiconductor innovation in the new era of AI requires transformative collaboration between universities and industry partners more than ever before,” said Ah-Hyung “Alissa” Park, Ronald and Valerie Sugar Dean of UCLA Samueli. “UCLA has a long history of pioneering semiconductor research and innovation, and this collaboration builds on that legacy by bringing together university research and industry expertise to advance the chip technologies that will define the future of computing while preparing the next generation of engineers.”

Applied’s new EPIC (Equipment and Process Innovation and Commercialization) Center in Silicon Valley represents the largest-ever U.S. investment in advanced semiconductor equipment R&D. The center is designed from the ground up to dramatically reduce the time it takes to commercialize breakthrough technologies from early-stage research to full-scale manufacturing. The facility is on track to become operational in 2026. Visit the EPIC Center website to learn more.

Forward-Looking Statements
This press release contains forward-looking statements, including those regarding Applied’s investment and growth strategies, the development of new materials and technologies, industry outlook and technology requirements, the plans and expectations for the EPIC Center, and other statements that are not historical facts. These statements and their underlying assumptions are subject to risks and uncertainties and are not guarantees of future performance. Factors that could cause actual results to differ materially from those expressed or implied by such statements include, without limitation: the demand for semiconductors and customers’ technology requirements; the ability to develop new and innovative technologies; the ability to obtain and protect intellectual property rights in key technologies; the ability to achieve the objectives of the EPIC Center; and other risks and uncertainties described in Applied’s filings with the Securities and Exchange Commission, including Applied’s most recent Forms 10-K, 10-Q and 8-K. All forward-looking statements are based on management’s current estimates, projections and assumptions, and Applied assumes no obligation to update them.

About Applied Materials
Applied Materials, Inc. (Nasdaq: AMAT) is the leader in materials engineering solutions that are at the foundation of virtually every new semiconductor and advanced display in the world. The technology we create is essential to advancing AI and accelerating the commercialization of next-generation chips. At Applied, we push the boundaries of science and engineering to deliver material innovation that changes the world. Learn more at www.appliedmaterials.com.

Contact: 
Ricky Gradwohl (editorial/media) 408.235.4676
Mike Sullivan (financial community) 408.986.7977

, /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today announced it achieved international average daily volume (ADV) of 9 million contracts in Q3 2026, up 22% from a year earlier.

Reflecting all trading reported outside the United States, this volume was driven largely by growth in Energy products, up 40%, Agricultural products, up 28%, and Equity Index products, up 24%.

"Markets remained volatile in the third quarter, with geopolitical issues fueling uncertainty and stoking inflation globally," said Julie Winkler, Chief Commercial Officer at CME Group. "Against this backdrop, customers around the world turned to CME Group to manage their risk, and the growth of our international volumes was testament to that."

International trading volume expanded by at least 20% in the period in all regions including Europe, Middle East and Africa (EMEA), Asia Pacific (APAC), and Latin America.

EMEA ADV increased 20% to 6.5 million contracts driven by:-

Energy products ADV up 33% Agricultural products ADV up 28% Equity Index products ADV up 20% APAC ADV increased by 28% to 2.1 million contracts driven by:-

Energy products ADV up 68% Equity Index products ADV up 32% Agricultural products ADV up 26% Interest Rate products ADV up 24% Canada ADV increased by 21% to 194,000 contracts driven by:-

Energy products ADV up 34% Interest Rate products ADV up 23% Equity Index products ADV up 22% Latin America ADV increased 24% to 188,000 contracts driven by:-

Agricultural products ADV up 49% Equity Index products ADV up 44% Energy products ADV up 23% Globally, CME Group reported an ADV of 29.4 million contracts in Q3 2026, up 16% over the same period in 2025. Q3 volumes in 2026 exceeded the prior Q3 record set in 2024. The increase in Q3 2026 ADV was largely driven by growth in Equity Index products, up 23%, and Foreign Exchange products, up 19%.

As the world's leading derivatives marketplace, CME Group (www.cmegroup.com) enables clients to trade futures, options, cash and OTC markets, optimize portfolios, and analyze data – empowering market participants worldwide to efficiently manage risk and capture opportunities. CME Group exchanges offer the widest range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange, cryptocurrencies, energy, agricultural products and metals.  The company offers futures and options on futures trading through the CME Globex platform, fixed income trading via BrokerTec and foreign exchange trading on the EBS platform.  In addition, it operates one of the world's leading central counterparty clearing providers, CME Clearing. 

CME Group, the Globe logo, CME, Chicago Mercantile Exchange, Globex, and E-mini are trademarks of Chicago Mercantile Exchange Inc.  CBOT and Chicago Board of Trade are trademarks of Board of Trade of the City of Chicago, Inc.  NYMEX, New York Mercantile Exchange and ClearPort are trademarks of New York Mercantile Exchange, Inc.  COMEX is a trademark of Commodity Exchange, Inc. BrokerTec is a trademark of BrokerTec Americas LLC and EBS is a trademark of EBS Group LTD. The S&P 500 Index is a product of S&P Dow Jones Indices LLC ("S&P DJI"). "S&P®", "S&P 500®", "SPY®", "SPX®", US 500 and The 500 are trademarks of Standard & Poor's Financial Services LLC; Dow Jones®, DJIA® and Dow Jones Industrial Average are service and/or trademarks of Dow Jones Trademark Holdings LLC. These trademarks have been licensed for use by Chicago Mercantile Exchange Inc. Futures contracts based on the S&P 500 Index are not sponsored, endorsed, marketed, or promoted by S&P DJI, and S&P DJI makes no representation regarding the advisability of investing in such products. All other trademarks are the property of their respective owners.

CME-G

SOURCE CME Group

Gold attempts breakout after punishing decline since late August
Dollar's historically stretched rally shows signs of losing momentum
Treasury futures attempt bottom following extreme oversold conditions
Gold bulls eye $4,225–$4,235 as first major upside target
Gold is attempting to break out after a punishing bearish period since late August, just as two of the key markets that contributed to its weakness are showing signs of potentially reversing.

US 10-year Treasury note futures look to be establishing a bottom, having hit extreme oversold conditions earlier this month, while the US Dollar Index has broken its short-term uptrend after becoming unusually stretched to the upside.

The question now is: can gold make the breakout stick?

Gold's relationship with the dollar and Treasury futures
As the correlation matrix below demonstrates, the US dollar has maintained a strong inverse relationship with gold, particularly over longer timeframes, with the 120-session correlation sitting at -0.86, while the relationship over the past month remains firm at -0.80.

Source: TradingView

While less consistent than the relationship with the US dollar, 10-year Treasury note futures have also demonstrated a positive correlation with gold over the past week and fortnight, strengthening dramatically to +0.89 over the past month. Futures are used as the preferred measure given they're directly tradable, unlike Treasury yields.

US dollar rally showing signs of exhaustion
Given the strength and persistence of the inverse relationship with the dollar, the chart below makes for interesting viewing, not only for those trading FX, but also precious metals.

Source: TradingView

After becoming historically stretched to the upside, with RSI (14) reaching 76.8, placing it in the highest 1.5% of observations since 2013, and the ATR (50) stretch exceeding four, ranking in the highest 5% of the dataset, there are signs the big dollar is starting to roll over.

RSI (14) has moved back below overbought territory and is setting lower highs, while the uptrend in place since early September has cracked. That doesn't mean the break will stick, but if it does, it points to a potential change in the dollar's trend, at least over the short to medium term.

Treasury futures showing signs of a bottom
It's not just the dollar that looks like it may be approaching a turning point.

US 10-year Treasury note futures are also showing signs of trying to carve out a bottom following a punishing selloff that saw the price fall below the lows set in 2023.

Source: TradingView

RSI (14) fell to 19.7 in late September, ranking among the lowest 0.5% of observations since 2016, while the ATR (50) stretch reached -5.08, placing it among the most extreme 2% of readings.

Noticeable downside wicks suggest buyers have been stepping in at lower levels, coinciding with a significant increase in trading volumes. While this raises the possibility of a turning point over the short to medium term, it's far too early to declare a definitive bottom.

Gold breakout gathers momentum

Source: TradingView

The four-hourly chart highlights the punishing bearish trend gold has endured since late August, falling more than $600 per ounce from its high just shy of $4,700.

However, after breaking to fresh multi-month lows earlier this week, the price rebounded sharply from support around $4,070. A period of grinding price action followed before today's breakout above downtrend resistance during Asian trade, with gold subsequently clearing $4,184.43, the October 7 high.

That level now becomes the immediate downside focal point. A pullback and bounce could provide an opportunity to initiate longs with a tight stop beneath for protection, initially targeting former support between $4,225 and $4,235. Beyond that, $4,300, $4,333.58 and $4,400 are the levels to watch.

Alternatively, a reversal back beneath $4,184.43 could open the door to shorts, initially targeting the broken August downtrend, followed by $4,116.30, a level that has acted as both support and resistance previously this year.

Like the price action, the oscillators are becoming more positive for the bulls. RSI (14) has moved rapidly above 50, while MACD has staged a bullish crossover and flipped positive, suggesting upside momentum is building and improving the prospects of the breakout sticking.

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. ("HCA" or the "Company") (NYSE: HCA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether HCA and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On July 14, 2026, HCA issued a press release reporting its preliminary financial and operating results for the second quarter of 2026. Among other items, HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in the Company's payer mix, which impacted revenue by approximately $400 million in the quarter. 

On this news, HCA's stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share on July 14, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Danielle Peyton

Pomerantz LLP

[email protected]

646-581-9980 ext. 7980

SOURCE Pomerantz LLP